Title |
Endometrial stem cells in regenerative medicine
|
---|---|
Published in |
Journal of Biological Engineering, August 2014
|
DOI | 10.1186/1754-1611-8-20 |
Pubmed ID | |
Authors |
Javad Verdi, Aaron Tan, Alireza Shoae-Hassani, Alexander M Seifalian |
Abstract |
First described in 2004, endometrial stem cells (EnSCs) are adult stem cells isolated from the endometrial tissue. EnSCs comprise of a population of epithelial stem cells, mesenchymal stem cells, and side population stem cells. When secreted in the menstrual blood, they are termed menstrual stem cells or endometrial regenerative cells. Mounting evidence suggests that EnSCs can be utilized in regenerative medicine. EnSCs can be used as immuno-modulatory agents to attenuate inflammation, are implicated in angiogenesis and vascularization during tissue regeneration, and can also be reprogrammed into induced pluripotent stem cells. Furthermore, EnSCs can be used in tissue engineering applications and there are several clinical trials currently in place to ascertain the therapeutic potential of EnSCs. This review highlights the progress made in EnSC research, describing their mesodermal, ectodermal, and endodermal potentials both in vitro and in vivo. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 3 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 124 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 21 | 17% |
Student > Ph. D. Student | 20 | 16% |
Researcher | 15 | 12% |
Student > Master | 12 | 10% |
Student > Postgraduate | 8 | 6% |
Other | 21 | 17% |
Unknown | 27 | 22% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 25 | 20% |
Agricultural and Biological Sciences | 24 | 19% |
Biochemistry, Genetics and Molecular Biology | 22 | 18% |
Engineering | 4 | 3% |
Immunology and Microbiology | 3 | 2% |
Other | 15 | 12% |
Unknown | 31 | 25% |